

CURRICULUM VITAE

Matteo Landriscina, M.D., Ph.D

2021

Birth: Bari (Italy) 24 Oct. 1968
Home address Via Lettini, 6 – 70059 Trani (BA), Italy
Work address Medical Oncology Unit, Department of Medical and Surgical Sciences,
University of Foggia, School of Medicine, Viale Pinto, 1 – 71100 Foggia,
Italy

Education

- MD with honor, Catholic University, July 1993, defending the thesis entitled: “Control of mitochondrial Superoxide-dismutase expression in rat Hepatocarcinoma: a model of oncosuppressor gene regulation”.
- Residency in Oncology, with honor, October 1997, defending the thesis entitled: “Mechanisms of angiogenesis in human colorectal cancer”.
- PhD in Oncology, February 2003, defending the thesis entitled: “Molecular mechanisms of angiogenesis”.

Positions held

- Apr. 1998 to April 2001: Postdoctoral Associate in the laboratory of Dr. Thomas Maciag, Center for Molecular Medicine, Maine Medical Center Research Institute, Portland (ME), USA.
- Nov. 2002 to Jan. 2004: Assistant Professor “on call” at the Unit of Medical Oncology, Institute of Internal Medicine, Catholic University, Rome.
- Jan. 2004 to June 2016: Assistant Professor of Medical Oncology at the Department of Medical and Surgical Sciences, University of Foggia.
- July 2016 to June 2020: Associate Professor of Medical Oncology at the Department of Medical and Surgical Sciences, University of Foggia.
- Feb. 2011 to now: Principal Investigator of a Translational Research Laboratory on Solid Tumors at the IRCCS-CROB of Rionero in Vulture.
- July 2020 to now: Full Professor of Medical Oncology at the Department of Medical and Surgical Sciences, University of Foggia.

Research Grants

- 2016-2018** P.I. of the Research Grant entitled “Cancer type-specific regulation of cell metabolism by TRAP1: impact on malignant phenotypes and drug resistance/design” funded by the Italian Association of Cancer Research (AIRC).
- 2014-2016** P.I. of the Research Grant entitled “Role of TRAP1 in the molecular and clinical features of human BRAF-driven colorectal and thyroid carcinomas: a novel molecular target” funded by the University of Foggia.
- 2013-2015** P.I. of the Research Grant entitled “TRAP1 controls stress-adaptive responses of cancer cells: a novel molecular target in drug resistance” funded by the Italian Association of Cancer Research (AIRC).
- 2012-2015** Co-P.I. of the Research Grant entitled “The role of TRAP1 in the resistance to anti-EGFR1 agents in human colorectal carcinoma” (GR-2010-2310057) funded by the Italian Ministry of Health. Young Researchers 2010 Grant.
- 2010-2011** Co-P.I. of the Research Grant PRIN 2008 entitled “The role of TRAP1 in favoring the resistance to anticancer agents in human

breast and colorectal tumors", funded by the Italian Government.
National Coordinator: Prof.ssa Paola Chiarugi.

- 2010-2012** P.I. of the Research Grant entitled "Role of TRAP1, a novel antiapoptotic gene, in the resistance to anticancer therapy in colon and breast tumors", funded by the Italian Association of Cancer Research (AIRC).
- 2009-2010** P.I. of the Research Grant entitled "Role of the mitochondrial chaperone TRAP1 in the resistance to anticancer agents which inhibit the signaling of EGFR superfamily receptor", funded by Fondazione Guido Berlucci.
- 2009-2011** Co-P.I. of the Research Grant entitled "Novel biomarkers for the early diagnosis of non-medullary familial thyroid carcinomas", funded by Lega Italiana per la Lotta ai Tumori (LILT); National Coordinator: Prof. Mauro Cignarelli.
- 2005-2006** Co-P.I. of the Research Grant entitled "Uomo e Salute", funded by Fondazione CARIME.
- 2004-2005** Co-P.I. of the Research Grant PRIN 2004 entitled "Redox-dependent mechanisms involved in the regulation of human thyroid and brain tumors", funded by the Italian Government.
National Coordinator: Prof.ssa Paola Chiarugi.

Clinical Activity

- 2002-Jan 2004: Medical Oncologist at the Unit of Clinical Oncology of the Institute of Internal Medicine, Catholic University of Rome.
- 2004-2011: Medical Oncology at the Unit of Hematology of the University of Foggia, School of Medicine, Riuniti Hospital, Foggia.
- 2012-2018: Coordinator the Medical Oncology Activity Program at the Unit of Medical Oncology of the University of Foggia, School of Medicine, Riuniti Hospital, Foggia.
- 2019-now: Director of the Unit of Medical Oncology and biomolecular Therapy of the University of Foggia, School of Medicine, Riuniti Hospital, Foggia.

Publications in International Journals

1. Ria F, **Landriscina M**, Galeotti T. Preparation of a monoclonal antibody against rat MnSOD, using a COOH-terminal peptide. **Biochemical and Biophysical Research Communications** 1993; 195:697-703. *I.F. 2.30, Q2*
2. Ria F, **Landriscina M**, Remiddi F, Galeotti T. Monoclonal antibody 35.8 recognizes human, mouse and rat MnSOD in western blot and immunostaining. **Biochemistry and Molecular Biology International** 1994; 33:107-115. *Q4 I.F. 3.14*
3. Borrello S, De Leo ME, **Landriscina M**, Palazzotti B, Galeotti T. Diethyldithiocarbamate treatment up-regulates manganese superoxidedismutase gene expression in rat liver. **Biochemical and Biophysical Research Communications** 1996; 22:546-549. *Q2 I.F. 2.30*
4. **Landriscina M**, Remiddi F, Ria R, Palazzotti B, De Leo ME, Iacoangeli M, Roselli R, Scerrati M, Galeotti T. The level of MnSOD is directly correlated with grading in brain tumours of neuroepithelial origin. **British Journal of Cancer** 1996; 74:1877-1885. *Q1 I.F. 4.84*
5. De Leo ME, **Landriscina M**, Palazzotti B, Borrello S, Galeotti T. Iron modulation of LPS induced manganese superoxidedismutase gene expression in rat liver. **FEBS Letters** 1997; 403:131-135. *Q1 I.F. 3.17*
6. **Landriscina M**, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F, Barone C. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth

factor in human colorectal cancer. **British Journal of Cancer** 1998; 78:765-770. **Q1 I.F. 4.84**

7. Barone C, Corsi DC, Pozzo C, Cassano A, Fontana T, Noviello MR, **Landriscina M**, Colloca G, Astone A. Treatment of patients with advanced gastric carcinoma with 5-fluorouracil-based or cisplatin-based regimen: two parallel phase II studies. **Cancer** 1998; 82:1460-1467. **Q1 I.F. 5.07**
8. Barone C, Corsi DC, Pozzo C, Cassano A, Alvaro G, Colloca G, **Landriscina M**, Astone A. Vinorelbine and alternating cisplatin and ifosfamide in the treatment of non-small cell lung cancer. **Oncology** 2000; 58:25-30. **Q2 I.F. 2.42**
9. Barone C, Cassano A, **Landriscina M**, Longo R, Astone A, Pozzo C. Bolus and infusional 5-fluorouracil combined with cisplatin in advanced gastric cancer. **Oncology Reports** 2000; 7(6):1305-1309. **Q2 I.F. 2.30**
10. Prudovsky I, **Landriscina M**, Soldi R, Bellum S, Small D, Andreeva V, Maciag T. FGF gene family and reporter gene chimeras to study nuclear translocation and non-classical exocytosis. **Methods in Enzymology** 2000; 327:369-382. **Q1 I.F. 2.09**
11. **Landriscina M**, Prudovsky I, Mouta Carreira C, Soldi R, Tarantini F, Maciag T. Amlexanox reversibly inhibits cell migration and proliferation and induces the Src-dependent disassembly of actin stress fiber *in vitro*. **Journal of Biological Chemistry** 2000; 275:32753-32762. **Q1 I.F. 6.176**
12. Tarantini F, Micucci I, Bellum S, **Landriscina M**, Garfinkel S, Prudovsky I, Maciag T. The precursor but not the mature form of IL1 α blocks the release of FGF1 in response to heat shock. **Journal of Biological Chemistry** 2001; 276: 5147-5151. **Q1 I.F. 6.176**
13. Ria F, **Landriscina M**, Remiddi F, Roselli R, Iacoangeli M, Scerrati M, Pani G, Borrello S, Galeotti T. The levels of manganese superoxide dismutase content is an independent prognostic factor for glioblastoma. Biological mechanism and clinical implications. **British Journal of Cancer** 2001; 84:529-534. **Q1 I.F. 4.84**
14. Mouta Carreira C, **Landriscina M**, Bellum S, Prudovsky I, Maciag T. The comparative release of FGF1 by hypoxia and temperature stress. **Growth Factors** 2001; 18(4):277-285. **Q1 I.F. 3.39**
15. **Landriscina M**, Soldi R, Bagalà C, Micucci I, Bellum S, Tarantini F, Prudovsky I, Maciag T. S100A13 participates in the release of FGF1 in response to heat shock in vitro. **Journal of Biological Chemistry** 2001;276(25):22544-22552. **Q1 I.F. 6.176**
16. **Landriscina M**, Bagalà C, Mandinova A, Soldi R, Micucci I, Bellum S, Prudovsky I, Maciag T. Copper Induces the Assembly of a Multiprotein Aggregate Implicated in the Release of FGF1 in Response to Stress. **Journal of Biological Chemistry**, 276(27); 25549-57, 2001. **Q1 I.F. 6.176**
17. Small D, Kovalenko D, Kacer D, Liaw L, **Landriscina M**, Di Serio C, Prudovsky I, Maciag T. Soluble Jagged 1 represses the function of its transmembrane form to induce the formation of the Src-dependent chord-like formation. **Journal of Biological Chemistry** 2001; 276(34): 32022-32030. **Q1 I.F. 6.176**
18. Cassano A, Bagalà C, Battelli C, Schinzari G, Quirino M, Ratto C, **Landriscina M**, Barone C. Expression of vascular endothelial growth factor, mitogen-activated Protein kinase and p53 in human colorectal cancer. **Anticancer Research** 2002; 22:2179-2184. **Q4 I.F. 1.83**
19. Mangiacasale R, Pittoggi C, Sciamanna I, Careddu A, Mattei E, Lorenzini R, **Landriscina M**, Barone C, Nervi C, Lavia P, Spadafora C. Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation. **Oncogene** 2003; 22:2750-2761. **Q1 I.F. 8.46**
20. Mandinova A, Bellum S, Bagalà C, Soldi R, Graziani I, **Landriscina M**, Tarantini F, Prudovsky I, Maciag T. S100A13 mediates the Cu²⁺-dependent stress-induced release

of IL1 α from both human U937 and NIH 3T3 cells. **Journal of Cell Science** 2003; 116:2687-2696. **Q2 I.F. 5.4**

21. Prudovsky I, Mandinova A, Soldi R, Bagalà C, Graziani I, **Landriscina M**, Tarantini F, Duarte M, Bellum S, Doherty H, Maciag T. The non-classical export routes: FGF1 and IL-1alpha point the way. **Journal of Cell Science** 2003; 116:4871-4881. **Q2 I.F. 5.4**
22. Cammarota G, Pirozzi GA, Martino A, Zuccalà G, Cianci R, Cuoco L, Ojetti V, **Landriscina M**, Montalto M, Vecchio FM, Gasbarrini G, Gasbarrini A. Reliability of the "immersion technique" during routine upper endoscopy for detection of abnormalities of duodenal villi in patients with dyspepsia. **Q1 Gastrointestinal Endoscopy** 2004; 60:223-228. **I.F. 5.37**
23. Sciamanna I*, **Landriscina M***, Pittoggi C, Quirino M, Mearelli C, Beraldi R, Mattei E, Serafino A, Cassano A, Sinibaldi-Vallebona P, Garaci E, Barone C, Spadafora C (*equal contribution). Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. **Oncogene** 2005; 24:3923-3931. **Q1 I.F. 8.46**
24. **Landriscina M**, Fabiano A, Altamura S, Bagalà C, Piscazzi A, Cassano A, Spadafora C, Giorgino F, Barone C, Cignarelli M. Reverse transcriptase inhibitors down-regulate cell proliferation *in vitro* and *in vivo* and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. **Journal of Clinical Endocrinology and Metabolism** 2005; 90(10):5663-5671. **Q1 I.F. 6.21**
25. **Landriscina M**, Schinzari G, Di Leonardo G, Quirino M, Cassano A, Lauriola L, D'Argento E, Scerrati M, Barone C. S100A13, a New Marker of Angiogenesis in Human Neuroectodermal Brain Tumors. **Journal of Neuro-oncology** 2006; 80(3):251-259. **Q2 I.F. 3.07**
26. **Landriscina M**, Modoni S, Fabiano A, Fersini A, Barone C, Ambrosi A, Cignarelli M. Cell differentiation and iodine-131 uptake in poorly differentiated thyroid tumour in response to nevirapine. **Lancet Oncology** 2006; 7(10):877-879. **Q1 I.F. 24.69**
27. Barone C, **Landriscina M**, Quirino M, Basso M, Pozzo C, Schinzari G, D'Argento E, Trigila N, Cassano A. Schedule-dependent activity of the 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: *in vitro* evidences and a phase I dose-escalating clinical trial. **British Journal of Cancer** 2007; 96(1):21-28. **Q1 I.F. 4.84**
28. **Landriscina M**, Spadafora C, Cignarelli M, Barone C. Anti-tumor activity of non-nucleosidic reverse transcriptase inhibitors **Current Pharmaceutical Design** 2007; 13(7):737-747 (invited contribution). **Q1 I.F. 3.45**
29. Modoni S, **Landriscina M**, Fabiano A, Fersini A, Urbano N, Ambrosi A, Cignarelli M. Re-induction of cell differentiation and ¹³¹I uptake in a poorly-differentiated thyroid tumour in response to the Reverse Transcriptase (RT) inhibitor nevirapine. **Cancer Biotherapy & Radiopharmaceuticals** 2007; 22(2):289-295. **Q2 I.F. 1.78**
30. Montesano Gesualdi N, Chirico G, Pirozzi G, Costantino E, **Landriscina M**, Esposito F. Tumor necrosis factor-associated protein 1 (Trap-1) protects cells from oxidative stress and apoptosis. **Stress** 2007; 10(4):342-350. **Q1 I.F. 2.72**
31. Casalino E, Calzaretti G, **Landriscina M**, Sblano C, Fabiano A, Landriscina C. The Nrf2 transcription factor contributes to the induction of alpha-class GST isoenzymes in liver of acute cadmium or manganese intoxicated rats: Comparison with the toxic effect on NAD(P)H:quinone reductase. **Toxicology** 2007; 237(1-3):24-34. **Q1 I.F. 3.62**
32. Prudovsky I, Tarantini F, **Landriscina M**, Neivandt D, Soldi R, Kirov A, Small D, Kathir KM, Rajalingam D, Kumar TK. Secretion without Golgi. **Journal of Cellular Biochemistry** 2008; 103(5):1327-1343. **Q2 I.F. 3.26**
33. Barone C, Bagalà C, **Landriscina M**. S100A13 (S100 calcium binding protein A13). **Atlas of Genetic and Cytogenetic in Oncology and Haematology** 2008; 12(6), 440-443. **Q4**

34. Landriscina M, Altamura S, Roca L, Gigante M, Piscazzi A, Cavalcanti E, Maiorano N, Barone C, Cignarelli M, Gesualdo L, Ranieri E. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. **International Journal of Cancer** 2008; 122(12):2842-2850. **Q1 I.F. 5.09**
35. Di Serio C, Doria L, Pellerito S, Prudovsky I, Massi D, Landriscina M, Marchionni N, Masotti G, Tarantini F. The release of Fibroblast Growth Factor-1 from melanoma cells requires copper ions and is mediated by phosphatidylinositol 3-kinase/Akt intracellular signalling pathway. **Cancer Letters** 2008; 267(1):67-74. **Q1 I.F. 5.62**.
36. Santodirocco M, Lombardi V, Fesce C, Palumbo G, Capalbo S, Landriscina M. Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: a case report. **Acta Oncologica** 2008; 47(8):1602-1604. **Q2 I.F. 3.0**
37. Landriscina M, Fabiano A, Lombardi V, Santodirocco M, Piscazzi A, Fersini A, De Vis K, Barone C, Cignarelli M. Nevirapine toxicity in non-HIV cancer patients. **Chemotherapy** 2008; 54(6):475-478. **Q2 I.F. 1.29**
38. Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C. Nevirapine Induces an Androgen-Dependent Phenotype in Hormone-Refractory Human Prostate Carcinoma Cells both *in vitro* and *in vivo*. **The Prostate** 2009; 69(7):744-754. **Q2 I.F. 3.57**
39. Graziani I, Doyle A, Sterling S, Kirov A, Tarantini F, Landriscina M, Kumar TK, Neivandt D, Prudovsky I. Protein folding does not prevent the non-classical export of FGF1 and S100A13. **Biochemical and Biophysical Research Communications** 2009;381(3):350-354. **Q3**
40. Costantino E, Maddalena F, Calise F, Piscazzi A, Tirino V, Fersini A, Ambrosi A, Neri V, Esposito F, Landriscina M. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptosis in human colorectal carcinoma cells. **Cancer Letters** 2009; 279(1):39-46. **Q1 I.F. 5.62**
41. Landriscina M, Piscazzi A, Maddalena F, Costantino E, Cassano A, Barone C. Mechanism of action and therapeutic targeting of mTOR pathway. **Journal of Digestive Oncology** 2009; 1(1):16-20. **Q4**
42. Landriscina M, Piscazzi A, Fabiano A, Maddalena F, Costantino E, Farese A, Bufo P, Cignarelli M. Targeting the EGFR1 signaling in human TSH-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype. **Thyroid** 2009; 19(6): 629-637. **Q1 I.F. 4.49**
43. Landriscina M, Maddalena F, Laudiero G, Esposito F. Adaptation to oxidative stress, chemoresistance and cell survival. **Antioxidants and Redox Signaling** 2009; 11(11):2701-16. **Q1 I.F. 7.41**
44. Landriscina M, Amoroso MR, Piscazzi A, Esposito F. Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. **Gynecologic Oncology** 2010; 117(2):177-182. **Q2 I.F. 3.77**
45. Landriscina M, Maddalena F, Fabiano A, Piscazzi A, La Macchia O, Cignarelli M. Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. **Anticancer Research** 2010; 30(2):473-480. **Q4 I.F. 1.83**
46. Massi D*, Landriscina M*, Piscazzi A, Cosci E, Kirov A, Paglierani M, Di Serio C, Mourmouras V, Fumagalli S, Biagioli M, Prudovsky I, Miracco C, Santucci M, Marchionni N, Tarantini F (*equal contribution). S100A13 is a new angiogenic marker in human melanoma. **Modern Pathology** 2010; 23(6):804-813. **Q1 I.F. 6.19**
47. Landriscina M, Laudiero G, Maddalena F, Amoroso MR, Piscazzi A, Cozzolino F, Monti M, Garbi C, Fersini A, Pucci P, Esposito F. Mitochondrial chaperone trap1 and the calcium binding protein sorcin interact and protect cells against apoptosis induced by antiproliferative agents. **Cancer Research** 2010; 70(16):6577-6586. **Q1 I.F. 9.33**

48. Natoli C, Ramazzotti V, Nappi O, Giacomini P, Palmeri S, Salvatore M, **Landriscina M**, Zilli M, Natali PG, Tinari N, Iacobelli S; on behalf of Consorzio Interuniversitario Nazionale per Bio-Oncologia (CINBO). Unknown primary tumors. **Biochimica Biophysica Acta – Reviews on Cancer** 2011; 16(1):13-24. **Q1 I.F. 7.85**
49. **Landriscina M**, Pannone G, Piscazzi A, Toti P, Fabiano A, Tortorella S, Occhini R, Ambrosi A, Bufo P, Cignarelli M. Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans. **Thyroid** 2011; 21(11):1227-1234. **Q1 I.F. 4.49**
50. **Landriscina M**, Esposito F. Insulin-resistant conditions: a favorable milieu for aggressive drug-resistant malignancies. **Journal of Gastrointestinal Oncology** 2011; 2(1):11-12. **Q4 I.F. 0.62**.
51. Maddalena F, Laudiero G, Piscazzi A, Secondo A, Scorziello A, Lombardi V, Matassa DS, Fersini A, Neri V, Esposito F, **Landriscina M**. Sorcin induces a drug-resistant phenotype in human colorectal cancer through by modulating Ca²⁺ homeostasis. **Cancer Research** 2011; 71(24):7659-7669. **Q1 I.F. 9.33**
52. Danza G, Di Serio C, Rosati F, Lonetto G, Sturli N, Kacer D, Pennella A, Ventimiglia G, Barucci R, Piscazzi A, Prudovsky I, **Landriscina M**, Marchionni N, Tarantini F. Notch signalling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. **Molecular Cancer Research**, 2012;10: 230-238 **Q2 I.F. 4.38**
53. Amoroso MR, Matassa DS, Laudiero G, Egorova AV, Polishchuk RS, Maddalena F, Piscazzi A, Paladino S, Sarnataro D, Garbi C, ***Landriscina M**, Esposito F (co-corresponding author). TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. **Cell Death and Differentiation** 2012;19(4):592-604. **Q1 I.F. 8.18**
54. Piscazzi A, Costantino E, Maddalena F, Natalicchio I, Gerardi AMT, Antonetti R, Cignarelli M, **Landriscina M**. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. **Journal of Clinical Endocrinology and Metabolism**, 2012; 97(6):E898-906. **Q1 I.F. 6.21**
55. Matassa DS, Amoroso MR, Maddalena F, ***Landriscina M**, Esposito F. New insights into TRAP1 pathway (*co-corresponding authors). **American Journal of Cancer Research**, 2012; 2(2):235-48. **Q2 I.F. 4.17**
56. Zupa A, Vita G, **Landriscina M**, Possidente L, Aieta M, Tartarone A, Improta G. Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC. **Medical Oncology** 2012; 29(5):3198-201. **Q2 I.F. 2.63**
57. Gerardi AM, Stoppino LP, Liso A, Macarini L, **Landriscina M**. Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma. **Oncology Letters** 2013; 5(3):975-977. **Q4 I.F. 1.55**
58. Maddalena F, Sisinni L, Lettini G, Condelli V, Matassa DS, Piscazzi A, Amoroso MR, La Torre G, Esposito F, **Landriscina M**. Resistance to paclitaxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1. **Molecular Oncology** 2013; 7(5):895-906. **Q1 I.F. 5.33**
59. Sciacovelli M, Guzzo G, Morello V, Frezza C, Zheng L, Nannini N, Calabrese F, Laudiero G, Esposito F, **Landriscina M**, Defilippi P, Bernardi P, Rasola A. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. **Cell Metabolism** 2013; 17(6):988-99. **Q1 I.F. 17.57**
60. Scutiero G, Loizzi V, Macarini L, **Landriscina M**, Greco P. Small cell carcinoma of the uterine cervix metastasising to the cerebellum. **Journal of Obstetrics and Gynaecology** 2013;33(6):639-41. **Q4 I.F. 0.55**
61. **Landriscina M**, Gerardi AM, Fersini A, Modoni S, Stoppino LP, Macarini L, Sanguedolce F, Bufo P, Neri V. Multiple skeletal muscle metastases from colon

carcinoma preceded by paraneoplastic dermatomyositis. **Case Reports in Medicine** 2013; 2013:392609. **Q3 I.F. 0.5**

62. Matassa DS, Amoroso MR, Agliarulo I, Maddalena F, Sisinni L, Paladino S, Romano S, Romano MF, Sagar V, Loreni F, ***Landriscina M**, Esposito F (*co-corresponding author). Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1. **Cell Death and Disease** 2013; 4:e851. **Q1 I.F. 5.01**
63. Pannone G, Santoro A, Pasquali D, Zamparese R, Mattoni M, Russo G, **Landriscina M**, Piscazzi A, Toti P, Cignarelli M, Lo Muzio L, Bufo P. The role of survivin in thyroid tumors: differences of expression in well-differentiated, non-well-differentiated, and anaplastic thyroid cancers. **Thyroid** 2014; 24(3):511-9. **Q1 I.F. 4.49**
64. Sisinni L, Maddalena F, Lettini G, Condelli V, Matassa DS, Esposito F, **Landriscina M**. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells. **International Journal of Oncology** 2014; 44(2):573-82. **Q1 I.F. 3.03**
65. Condelli V, Lettini G, Patitucci G, D'Auria F, D'Amico M, Vita G, Musto P, Cuomo C, **Landriscina M**. Validation of vacuum-based refrigerated system for biobanking tissue preservation: analysis of cellular morphology, protein stability, and RNA quality. **Biopreservation and Biobanking** 2014; 12(1):35-45. **Q4 I.F. 1.34**
66. Natalicchio MI, Improta G, Zupa A, Cursio OE, Stampone E, Possidente L, Gerardi AMT, Vita G, Martini M, Cassano A, Piccoli C, Romito S, Aieta M, Antonetti R, Barone C, **Landriscina M**. Relevance of pyrosequencing evaluation of low frequency KRAS mutant alleles for the selection of EGFR therapy in metastatic colorectal cancer. **Future Oncology** 2014;10(5):713-23. **Q3 I.F. 2.48**
67. Matassa DS, Agliarulo I, Amoroso MR, Maddalena F, Sepe L, Ferrari MC, Sagar V, D'Amico S, Loreni F, Paoletta G, ***Landriscina M**, Esposito F (*co-corresponding author). TRAP1-dependent regulation of p70S6K is involved in the attenuation of protein synthesis and cell migration: Relevance in human colorectal tumors. **Molecular Oncology** 2014; 8(8):1482-94 **Q1 I.F. 5.33**
68. Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P; "FOLLOW-UP" Study Group. Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey. **PLoS One** 2014; 9(4):e94063 **Q1 I.F. 3.23**
69. Amoroso MR, Matassa DS, Sisinni L, Lettini G, ***Landriscina M**, Esposito F (*co-corresponding author). TRAP1 revisited: novel localizations and functions of a 'next-generation' biomarker (review). **International Journal of Oncology** 2014; 45(3):969-77. **Q2 I.F. 3.03**
70. Condelli V, Piscazzi A, Sisinni L, Matassa DS, Maddalena F, Lettini G, Simeon V, Palladino G, Amoroso MR, Trino S, Esposito F, **Landriscina M**. TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors. **Cancer Research** 2014; 74(22):6693-704. **Q1 I.F. 9.329**
71. Agliarulo I, Matassa DS, Amoroso MR, Maddalena F, Sisinni L, Sepe L, Ferrari MC, Arzeni D, Avolio R, Paoletta G, ***Landriscina M**, Esposito F (*co-corresponding author). TRAP1 controls cell migration of cancer cells in metabolic stress conditions: Correlations with AKT/p70S6K pathways. **Biochimica Biophysica Acta – Molecular Cell Research** 2015; 1853(10 Pt A). **Q1 I.F. 5.128**
72. Condelli V, Maddalena F, Sisinni L, Lettini G, Matassa DS, Piscazzi A, Palladino G, Amoroso MR, Esposito F, **Landriscina M**. Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma. **Oncotarget** 2015;6(26):22298-309 **Q1 I.F. 5,008**

73. Sisinni L, **Landriscina M**. The role of human chorionic gonadotropin as tumor marker: biochemical and clinical aspects. **Advances in Experimental Medicine and Biology**, 2015; 867:159-76. **Q2 I.F. 1.96**
74. Maddalena F, Lettini G, Gallicchio R, Sisinni L, Nardelli A, Venetucci AA, Storto G, **Landriscina M**. Evaluation of Glucose Uptake in Normal and Cancer Cell Lines by Positron Emission Tomography. **Molecular Imaging** 2015; 14:490-8. **Q3 I.F. 1.96**
75. **Landriscina M**, Natalicchio MI, Lamacchia O, Conserva A, Piscazzi A, Ciampolillo A, Zingrillo M, Pennella A, Bufo P, Vita G, Antonetti R, Maiorano E, Giorgino G, Cignarelli M. RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: a retrospective study. **Oncology Letters** 2015; 1875-1881. **Q4 I.F. 1.55**
76. Denise C, Paoli P, Calvani M, Taddei ML, Giannoni E, Kopetz S, Kazmi SM, Pia MM, Pettazzoni P, Sacco E, Caselli A, Vanoni M, **Landriscina M**, Cirri P, Chiarugi P. 5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. **Oncotarget** 2015, 6(39):41706-21. **Q1 I.F. 6.36**
77. Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C, Faicchia D, Maddalena F, Simeon V, Agliarulo I, Zanini E, Mazzoccoli C, Recchi C, Stronach E, Marone G, Gabra H, Matarese G, **Landriscina M***, Esposito E (*co-corresponding author). Oxidative metabolism drives metainflammation-induced platinum resistance in ovarian cancer. **Cell Death and Differentiation** 2016 1;23(9):1542-54. **Q1 I.F. 8.34**
78. Palladino G, Pannone G, Notarangelo T, Piscazzi A, Lamacchia O, Sisinni L, Spagnoletti G, Toti P, Santoro A, Storto G, Bufo P, Cignarelli M, Esposito E, **Landriscina M**. TRAP1 regulates cell cycle and apoptosis during thyroid carcinoma progression. **Endocrine Related Cancer**, 2016;23(9):699-709. **Q1 I.F. 5.267**
79. Lettini G, Sisinni L, Condelli V, Matassa DS, Simeon V, Maddalena F, Gemei M, Lopes E, Vita G, Del Vecchio L, Esposito F, **Landriscina M**. TRAP1 regulates stemness through Wnt/ β -Catenin pathway in human colorectal carcinoma. **Cell Death and Differentiation**, 2016; 23(11):1792-1803. **Q1 I.F. 8.34**
80. Gallicchio R, Nardelli A, Mainenti P, Nappi A, Capacchione D, Simeon V, Sirignano C, Abbruzzi F, Barbato F, **Landriscina M**, Storto G. Therapeutic Strategies in HCC: Radiation Modalities. **Biomed Research International** 2016;2016:1295329.doi: 10.1155/2016/1295329. **Q2 I.F. 2.476**
81. Amoroso MR, Matassa DS, Agliarulo I, Avolio R, Lu H, Sisinni L, Lettini G, Gabra H, ***Landriscina M**, Esposito F (*co-corresponding author). TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition. **Cell Death and Disease** 2016;7(12):e2522. **Q1 I.F. 5.965**
82. Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, **Landriscina M**, Vendemiale G, Serviddio G. DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. **PLoS One** 2016;11(12):e0167934. **Q2 I.F. 3.54**
83. Possidente L, **Landriscina M**, Patitucci G, Borgia L, Lalinga V, Vita G. ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features. **Medical Oncology** 2017; 34(5):76. **Q2 I.F. 2.634**
84. Maddalena F, Simeon V, Vita G, Bochicchio A, Possidente L, Sisinni L, Lettini G, Condelli V, Matassa DS, Bergolis VL, Fersini A, Romito S, Aieta M, Ambrosi A, Esposito F, **Landriscina M**. TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma. **Oncotarget** 2017;8(13):21229-21240. **Q1 I.F. 5.080**
85. Amoroso MR, Matassa DS, Agliarulo I, Avolio R, Maddalena F, Condelli V, ***Landriscina M**, Esposito F (*co-corresponding author). Stress-Adaptive Response in Ovarian Cancer Drug Resistance: Role of TRAP1 in Oxidative Metabolism-Driven Inflammation. **Advances in Protein Chemistry and Structural Biology**, 2017; 108: 163-198. **Q2 I.F. 3.036**

86. Sisinni L, Maddalena F, Condelli V, Pannone G, Simeon V, Lopes V, Li Bergolis V, Piscazzi A, Matassa DS, Mazzoccoli C, Nozza F, Lettini G, Amoroso MR, Bufo P, Esposito F, **Landriscina M**. TRAP1 controls cell cycle progression through the regulation of CDK1 and MAD2 expression/ubiquitination in human breast, colon and lung carcinomas. **Journal of Pathology** 2017, 243(1):123-134. **Q1 I.F.** 6.253
87. Lettini G, Maddalena F, Sisinni L, Condelli V, Matassa Swann D, Costi MP, Simoni D, Esposito F, **Landriscina M**. TRAP1: A viable therapeutic target for future cancer treatments? **Expert Opinion on Therapeutic Targets** 2017, 21(8):805-815. **Q1 I.F.** 3.974
88. Liso A, Castellani S, Massenzio F, Trotta R, Pucciarini A, Bigerna B, De Luca P, Zoppoli P, Castiglione F, Palumbo MC, Stracci F, **Landriscina M**, Specchia G, Bach LA, Conese M, Falini B. Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of IGFBP6. **Oncotarget** 2017, 8(37):60826-60840. **Q1 I.F.** 4.790
89. Notarangelo T, Sisinni L, Condelli V, **Landriscina M**. Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF-mutated thyroid carcinoma cells. **Cancer Cell International** 2017;17:86. **Q2 I.F.** 3.960
90. Maddalena F, Lettini G, Esposito F, **Landriscina M**. RAD6: A new target to overcome platinum resistance in ovarian cancer? 2017 **Translational Cancer Research** 2017;6:S1476-S1479. **Q4 I.F.** 1.67
91. Sanguedolce F, **Landriscina M**, Ambrosi A, Tartaglia N, Cianci P, Di Millo M, Carrieri G, Bufo P, Cormio L. Bladder Metastases from Breast Cancer: Managing the Unexpected. A Systematic Review. **Urologia Internationalis** 2018;101(2):125-131. **Q2 I.F.** 1.508
92. Improta G, Zupa A, Natalicchio MI, Sisinni L, Marinaccio A, Bozza G, Vita G, Aieta M, **Landriscina M**. Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. **Medical Oncology** 2018, 35(3):28. **Q2 I.F.** 3.252
93. Spagnoletti G, Li Bergolis V, Piscazzi A, Giannelli F, Condelli V, Sisinni L, Bove G, Storto G, **Landriscina M**. Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells. **Tumour Biology** 2018;40(4):1010428318770957. **Q2 I.F.**
94. Matassa DS, Agliarulo I, Avolio R, ***Landriscina M**, Esposito F (*co-corresponding author). TRAP1 Regulation of Cancer Metabolism: Dual Role as Oncogene or Tumor Suppressor. **Genes** (Basel). 2018 5;9(4). pii: E195 **Q2 I.F.** 3.331
95. Rondanin R, Lettini G, Oliva P, Baruchello R, Costantini C, Trapella C, Simoni D, Bernardi T, Sisinni L, Pietrafesa M, Ponterini G, Costi MP, Vignudelli T, Luciani R, Matassa DS, Esposito F, **Landriscina M**. New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting. **Bioorganic & Medicinal Chemistry Letters** 2018, 28(13):2289-2293. **Q3 I.F.** 2,450
96. Roviello G, Imperatori M, Aieta M, Sollitto F, **Landriscina M**. Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough? **Journal of Thoracic Disease**, 2018;10:S2114-S2118. **Q3 I.F.** 2.027
97. Notarangelo T, Sisinni L, Trino S, Calice G, Simeon, **Landriscina M**. IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells. **Cancer Letters** 2018;433:147-155. **Q1 I.F.** 6.508
98. Sanguedolce F, Cormio A, Calo B, **Landriscina M**, Carvalho-Dias E, Cormio L. Micropapillary bladder cancer, a variant histology of the elderly **Journal of Gerontology and Geriatrics** 2018;66(4):222-227 **Q3 IF.** 2.611
99. Avolio R, Järvelin AI, Mohammed S, Agliarulo I, Condelli V, Zoppoli P, Calice G, Sarnataro D, Bechara E, Tartaglia GG, **Landriscina M**, Castello A, Esposito F, Matassa

- DS. Protein Syndesmos is a novel RNA-binding protein that regulates primary cilia formation. **Nucleic Acids Res.** 2018;46(22):12067-12086. **Q1 I.F.** 11.147
100. Pezzicoli G, Ummarino A, Maddalena F, Villani R, Barret E, **Landriscina M.** Unmet clinical questions in elderly patients with locally advanced and metastatic bladder cancer **Journal of Gerontology and Geriatrics** 2018;66(4): 253-259 **Q4 I.F.** 2.611
101. Sisinni L, Pietrafesa M, Lepore S, Maddalena F, Condelli V, Esposito F, **Landriscina M.** Endoplasmic Reticulum Stress and Unfolded Protein Response in Breast Cancer: The Balance between Apoptosis and Autophagy and Its Role in Drug Resistance. **International Journal of Molecular Science** 2019;20(4)E857. **Q1 I.F.** 4.183
102. Gallicchio R, Mastrangelo PA, Nardelli A, Mainenti PP, Colasurdo AP, **Landriscina M,** Guglielmi G, Storto G. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why. **Tumori** 2019; 105(5):367-377. **Q4 I.F.** 1.234
103. Condelli V, Crispo F, Pietrafesa M, Lettini G, Matassa DS, Esposito F, ***Landriscina M,** Maddalena F (*Corresponding author). HSP90 Molecular Chaperones, Metabolic Rewiring, and Epigenetics: Impact on Tumor Progression and Perspective for Anticancer Therapy. **Cells.** 2019;8(6):E532. **Q1 I.F.** 5.656
104. Crispo F, Condelli V, Lepore S, Notarangelo T, Sgambato A, Esposito F, Maddalena F, **Landriscina M.** Metabolic Dysregulations and Epigenetics: A Bidirectional Interplay that Drives Tumor Progression. **Cells** 2019;8(8): E798. **Q1 I.F.** 5.656
105. Crispo F, Notarangelo T, Pietrafesa M, Lettini G, Storto G, Sgambato A, Maddalena F, **Landriscina M.** BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives. **Cancers (Basel).** 2019;11(9):E1388. **Q1 I.F.** 6.16
106. Pietrafesa M, Maddalena F, Possidente L, Condelli V, Zoppoli P, Li Bergolis V, Rodriquenz MG, Aieta M, Vita G, Esposito F, **Landriscina M.** Gene Copy Number and Post-Transductional Mechanisms Regulate TRAP1 Expression in Human Colorectal Carcinomas. **Internationa Journal of Molecular Science** 2019;21(1):E145. **Q1 I.F.** 4.183
107. Lepore S, Lettini G, Condelli V, Sisinni L, Piscazzi A, Simeon V, Zoppoli P, Pedicillo MC, Natalicchio MI, Pietrafesa M, **Landriscina M.** Comparative Gene Expression Profiling of Tobacco-Associated HPV-Positive versus Negative Oral Squamous Carcinoma Cell Lines. **International Journal of Medical Science** 2020;17(1):112-124. **Q2 I.F.** 1.42
108. Avolio R, Matassa DS, Criscuolo D, ***Landriscina M,** Esposito F (*co-corresponding author). Modulation of Mitochondrial Metabolic Reprogramming and Oxidative Stress to Overcome Chemoresistance in Cancer. **Biomolecules** 2020;10(1):E135. **Q1 I.F.** 4.694
109. Lettini G, Lepore S, Crispo F, Sisinni L, Esposito F, **Landriscina M.** Heat shock proteins in cancer stem cell maintenance: A potential therapeutic target? **Histol Histopathol.** 2020;35(1):25-37. **Q2 I.F.** 1.77
110. Lettini G, Pietrafesa M, Lepore S, Maddalena F, Crispo F, Sgambato A, Esposito F, **Landriscina M.** Heat shock proteins in thyroid malignancies: Potential therapeutic targets for poorly-differentiated and anaplastic tumours? **Molecular and Cellular Endocrinology** 2020;502:110676. **Q2 I.F.** 3.693
111. Criscuolo D, Avolio R, Calice G, Laezza C, Paladino S, Navarra G, Maddalena F, Crispo F, Pagano C, Bifulco M, **Landriscina M,** Matassa DS, Esposito F. Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer. **Cells** 2020;9(4):828. **Q1 I.F.** 5.656
112. Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, Sgambato A, Esposito F, **Landriscina M.** *IDH1* Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives. **Molecules** 2020;25(16):3754. **Q1 I.F.** 3.267

113. Lettini G, Condelli V, Pietrafesa M, Crispo F, Zoppoli P, Maddalena F, Laurenzana I, Sgambato A, Esposito F, **Landriscina M**. TRAP1 Regulates Wnt/ β -Catenin Pathway through LRP5/6 Receptors Expression Modulation. **International Journal Molecular Science** 2020;21(20):7526. **Q1 I.F. 4.183**
114. Maddalena F, Condelli V, Matassa DS, Pacelli C, Scrima R, Lettini G, Li Bergolis V, Pietrafesa M, Crispo F, Piscazzi A, Storto G, Capitanio N, Esposito F, **Landriscina M**. TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas. **Molecular Oncology** 2020;14(12):3030-3047. **Q1 I.F. 6.287**
115. Condelli V, Calice G, Cassano A, Basso M, Rodriquenz MG, Zupa A, Maddalena F, Crispo F, Pietrafesa M, Aieta M, Sgambato A, Tortora G, Zoppoli P, **Landriscina M**. Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas. **Cancers** 2021,13,158. **Q1 I.F. 6.16**

Publications in other Journals

116. **Landriscina M**. Control of mitochondrial Superoxidedismutase expression in rat Hepatocarcinoma: a model of oncosuppressor gene regulation. **Acta Medica Romana** 1993; 31:531-568.
117. Borrello S, De Leo ME, **Landriscina M**, Remiddi F, Ria F, Palazzotti B, Galeotti T. Induzione con LPS della Manganese Superossido Dismutasi in HCC di ratto. **Acta Medica Romana** 1994; 32:633-642.
118. Barone C, Cassano A, Torino F, **Landriscina M**. Etiology of hepatocarcinoma: the viruses' role. **Acta Medica Romana** 1996; 34:102-104
119. **Landriscina M**, Remiddi F, Ria F, Palazzotti B, De Leo ME, Iacoangeli M, Roselli R, Scerrati M, Galeotti T. Increased expression of manganese-superoxidedismutase in brain neuroepithelial tumors: a new marker of progression? **Acta Medica Romana** 1997; 35:1-12
120. Cassano A, Astone A, **Landriscina M**, Mancini M, Calandrelli A, Governato I, Barone C. Triple modulation of 5-fluorouracil with methotrexate, folinic acid and cisplatin in the treatment of advanced gastric cancer: a phase II study. **Acta Medica Romana** 1997; 35,201-207
121. **Landriscina M**, Piscazzi A, Maddalena F, Costantino E, Cassano A, Barone C. Mechanism of action and therapeutic targeting of mTOR pathway **Journal of Digestive Oncology** 2009; 1(1):16-20
122. Maddalena F, Piscazzi A, Esposito F, **Landriscina M**. Novel strategies to improve the efficacy of anticancer agents in human colorectal carcinoma. **European Oncology** 2010; 6:55-59

Book Chapters

123. Borrello S, De Leo ME, Piccirillo G, Ria F, Pani G, **Landriscina M**, Galeotti T, Wohlrab H. Mechanism of defective gene expression of MnSOD in cancer cells. In: **Frontiers of Reactive Oxygen Species in Biology and Medicine**, K. Asada and T. Yoshikawa eds Elsevier Science, Amsterdam, p. 311, 1994
124. Borrello S, De Leo ME, Piccirillo G, Ria F, Pani G, **Landriscina M**, Galeotti T, Wohlrab H. Altered gene expression of MnSOD in Hepatocarcinomas. In: **The Oxygen paradox**, K.J.A. Davies and F. Ursini Ed., Cleup University press, Padova, p. 357-364, 1995
125. **Landriscina M**, Schinzari G, Cassano A, Di Leonardo G, Pozzo C, Barone C. Biological mechanisms and clinical significance of angiogenesis in colorectal cancer. In:

Recent Research Developments in Cancer, SG Pandalai, Ed. Transworld Research Network, 2003

126. **Landriscina M**, Fabiano A, Piscazzi A, Bagalà C, Altamura S, Maiorano N, Giorgino F, Barone C, Cignarelli M. The role of RT inhibitors as a novel molecular targeted treatment in the management of poorly differentiated thyroid tumors. In: **Focus on Thyroid Cancer**, Nova Science Publishers, 2006
127. Di Leonardo G, **Landriscina M**, Schinzari G, Quirino M, Cassano A, D'Argento E, Lauriola L, Scerrati M, Prudovsky I, Barone C. The activation of the S100A13/FGF1 release pathway: a potential mechanism of tumor progression in human brain gliomas. In: **Trends in Signal Transduction**, Nova Science Publishers, 2007
128. Barone C, **Landriscina M**, Cassano A. Colorectal cancer: optimization of the combination of 5-fluorouracil and irinotecan. In "**Methods of Cancer Diagnosis, Therapy, and Prognosis**" Editor: M.A. Hayat, Kean University, Union, New Jersey, USA Series: "Methods of Cancer Diagnosis, Therapy, and Prognosis"; Elsevier Academic Press, 2008
129. Piscazzi A, Fabiano A, Maddalena F, Costantino E, Farese A, Cignarelli M, **Landriscina M**. The role of EGF signaling in the progression toward a poorly-differentiated mesenchymal-like phenotype in thyroid carcinoma cells. In: **Handbook of Cell Proliferation**, Nova Science Publishers, 2009
130. Lombardi V, **Landriscina M**. I farmaci adiuvanti. In: **Manuale sulle Cure Palliative**. Edicare Publishing, 2011